Industries
Enterprise AI for Pharmaceuticals & Healthcare
AI in pharmaceuticals and healthcare is applied chiefly to the documentation layer — clinical trial records, regulatory submissions, standard operating procedures and safety narratives — where accuracy, traceability and version control are regulated requirements rather than preferences.
Drug development produces documentation at a scale that is difficult to convey. A single submission runs to tens of thousands of pages assembled from protocols, study reports, safety narratives and manufacturing records, every one of which must be internally consistent, correctly cross-referenced and traceable to source. The assembly and checking of that material is a substantial share of the cost and timeline, and it is performed by highly qualified people doing work that is mostly reading.
The same pattern repeats through clinical operations and pharmacovigilance. Protocol deviations are found by reading monitoring reports. Adverse events hide in free-text clinical notes. A protocol amendment means checking every downstream document it touches.
This is where AI earns its place in the sector — not in discovery, where the claims tend to outrun the evidence, but in the documentation layer, where the work is well defined, the volume is enormous, and a system that is traceable can be validated.
Where it applies
The applications with the clearest business case are the ones where the required output is already specified and the effort is assembly, checking and cross-referencing.
- Clinical trial document review, extraction and consistency checking across study documentation
- Regulatory submission preparation, with cross-referencing and traceability to source
- Adverse event and safety signal detection from unstructured clinical notes
- Protocol and SOP retrieval that answers from the current effective version and cites it
- Protocol amendment impact analysis across downstream documents
- Medical and scientific literature review and monitoring
- Manufacturing batch record review and deviation identification
Validation and GxP
Systems touching GxP processes have to be validated, and a non-deterministic component makes that harder without making it impossible. The approach is to constrain the system so its behaviour is specifiable and testable: define the intended use narrowly, retrieve rather than recall so outputs are grounded in controlled documents, require citations, hold a versioned evaluation suite with recorded results, and keep a human decision point on anything with a regulatory consequence.
Version control is critical and frequently underestimated. A system that answers from a superseded protocol is worse than useless, so effective-version handling is enforced in the retrieval layer rather than left to the corpus being tidy.
Patient and trial data
Much of this material cannot be transmitted to a third-party endpoint under any circumstances. Private deployment inside your own boundary removes the question, and in air-gapped or strictly segregated environments it is the only viable architecture. De-identification is applied at ingestion where the use case permits, and access controls in the source systems are enforced in retrieval.
Typical applications in pharma & healthcare.
- Clinical trial document review and cross-document consistency checking
- Regulatory submission assembly and cross-referencing
- Adverse event detection from unstructured clinical notes
- Protocol and SOP assistants answering from the current effective version
- Protocol amendment downstream impact analysis
- Scientific literature monitoring and review
- Batch record review and manufacturing deviation identification
- Medical information response drafting with cited sources
Pharma & Healthcare, answered.
The questions that come up on almost every first call in this sector.
Can a system with a language model in it be validated for GxP use?
Yes, with the right constraints. Narrow the intended use, ground outputs in controlled documents through retrieval rather than model recall, require citations, maintain a versioned evaluation suite with recorded results, and keep a human decision point on anything with regulatory consequence. Validation then assesses a specified, testable system. What cannot be validated is an open-ended assistant with no defined intended use — which is why we scope these deployments tightly.
How do you stop it answering from a superseded protocol version?
Effective-version handling is enforced in the retrieval layer: documents carry version and effective-date metadata, retrieval filters on it, and superseded versions are excluded from answers unless a user explicitly asks for history. Answering from an out-of-date document is the single most damaging failure mode in this sector, so it is designed against rather than left to corpus hygiene.
Can this run without patient or trial data leaving our environment?
Yes, and for most of this work it must. Open-weight models deployed inside your own infrastructure — including air-gapped environments — keep all content within your boundary. De-identification is applied at ingestion where the use case permits, and source-system access controls are enforced in retrieval.
Does the system make safety or regulatory determinations?
No. It surfaces candidates, assembles evidence and drafts with citations; qualified people determine. In pharmacovigilance that means flagging potential signals in free text for assessment rather than adjudicating them. The value is in making sure nothing is missed in a volume of text no team can read exhaustively, not in replacing the assessment.
What we build for this sector.
Tell us what you're trying to solve.
Describe the workflow, the data behind it, and what a good outcome looks like. We read every message and reply personally.